Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
The panel shares some final thoughts on unmet needs and the future of CLL treatment.
ABSTRACT: Disease progression or recurrence after a period of remission can be a challenging event for individuals seeking cancer treatment. Those referred for possible phase 1 trial enrollment are often motivated to participate in these studies with hope for a cure despite approximately 5% response rates in this setting. Addressing such commonly held misunderstandings during the initial evaluation for phase 1 trial eligibility could provide a valuable opportunity to improve physician communication by identifying signs of distress or psychiatric conditions, addressing underlying psychological biases, and encouraging adaptive coping strategies.
Laura S. Wood, MSN, RN, OCN, spoke to Physician's Education Resource regarding resources to increase clinical trial awareness and participation.
Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.
Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Although female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.
Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.
Shilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Panelists discuss how thoracic oncologists are adapting to a rapidly evolving treatment landscape for lung cancer, focusing on the integration of novel therapies and the importance of biomarker-driven approaches in patient care.
Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, highlighting the challenges of the initial diagnostic process, and explore the impact of fatigue and brain fog on her daily life. They also address how clinicians assess the severity of these symptoms during consultations and what they indicate about disease progression or treatment needs.
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
In a recent Hot Topics article, reimbursement rates for Medicare physicians are discussed, and how it will impact their practice.
Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Kira MacDougall, MD, and Muhammad Rafay Khan Niazi, MD, spoke with CancerNetwork® about their research into the significance of peripheral blood biomarkers of response to immunotherapy in non–small cell lung cancer published in the journal ONCOLOGY®.
Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.
Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.
CancerNetwork® spoke with Quita Highsmith and Monica Baskin, MD, about the Advancing Inclusive Research Alliance and efforts to include more diverse populations in clinical trials.